Literature DB >> 25653965

Comparative study of renal protective effects of allopurinol and N-acetyl-cysteine on contrast induced nephropathy in patients undergoing cardiac catheterization.

Ashutosh Kumar1, Goru Bhawani2, Neera Kumari3, Kasturi Sn Murthy4, Vinod Lalwani5, Ch Narasimha Raju5.   

Abstract

UNLABELLED: Objectives : To evaluate the difference in the renal protective effects of allopurinol and n-acetyl cysteine along with saline hydration in patients of contrast induced nephropathy (CIN) post cardiac interventions.
BACKGROUND: CIN remains a common complication of cardiac procedures. Radio contrast agents can cause a reduction in renal function that may be related to oxidative stress underlining various patho- physiologies. Conflicting evidence suggests that administration of allopurinol, a xanthine oxidase inhibitor can prevent CIN.
MATERIALS AND METHODS: This is a study of 500 patients undergoing angiography and coronary revascularisation in patients showing significant coronary block. The angiography positive patients (275) were prospectively randomised to different treatment protocol to study for their reno-protective effect. The patients received either of the three drugs saline hydration (SH, 1ml/kg/hr), n-acetylcysteine (SH+NAC, 600 mg bd) or Allopurinol (SH+ALLP, 300 mg/day) 12 hours before and after administration of radio contrast agent. Levels of serum creatinine and blood urea of the 275 patients recorded at 24 hour interval were noted post angioplasty over a course of 5 days in patients receiving either omnipaque (125) or visipaque (150) contrast media. All the 500 patients were also assessed for development of any kind of adverse drug effects/reactions with the two contrast media.
RESULTS: CIN occurred in 56 of 500 the patients (10.6%) who underwent angiography and 49 of 275 patients (17.8%) who underwent angioplasty. In the omnipaque group CIN occurred in 16/40, 8/40, nil/45 in patients receiving SH, NAC plus SH and SH plus ALLP respectively. In the visipaque group CIN occurred in 15/50, 10/50, nil/50 in the three treatments groups respectively. Allopurinol maintained a consistent fall in the serum creatinine &amp; blood urea levels from the baseline values from the end of the 1(st) day (p < .01 &amp; .001) in both the category. Visipaque proved to be better dye than omnipaque with less adverse drug effects/ reactions.
CONCLUSION: Prophylactic oral administration of allopurinol (300 mg/day) along with hydration is better than n-acetylcysteine and saline hydration alone for protection against CIN in patients undergoing coronary procedures.

Entities:  

Keywords:  Allopurinol; Contrast nephropathy; Omnipaque; Percutaneous coronary interventions; Visipaque

Year:  2014        PMID: 25653965      PMCID: PMC4316271          DOI: 10.7860/JCDR/2014/9638.5255

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  29 in total

1.  Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats.

Authors:  Laura G Sánchez-Lozada; Edilia Tapia; José Santamaría; Carmen Avila-Casado; Virgilia Soto; Tomás Nepomuceno; Bernardo Rodríguez-Iturbe; Richard J Johnson; Jaime Herrera-Acosta
Journal:  Kidney Int       Date:  2005-01       Impact factor: 10.612

2.  Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells.

Authors:  Duk-Hee Kang; Sung-Kwang Park; In-Kyu Lee; Richard J Johnson
Journal:  J Am Soc Nephrol       Date:  2005-10-26       Impact factor: 10.121

3.  Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality.

Authors:  P A McCullough; R Wolyn; L L Rocher; R N Levin; W W O'Neill
Journal:  Am J Med       Date:  1997-11       Impact factor: 4.965

Review 4.  Hyperuricemia and incident hypertension: a systematic review and meta-analysis.

Authors:  Peter C Grayson; Seo Young Kim; Michael LaValley; Hyon K Choi
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-01       Impact factor: 4.794

Review 5.  Uric acid and cardiovascular disease: a renal-cardiac relationship?

Authors:  B F Culleton
Journal:  Curr Opin Nephrol Hypertens       Date:  2001-05       Impact factor: 2.894

6.  Dosing of contrast material to prevent contrast nephropathy in patients with renal disease.

Authors:  R G Cigarroa; R A Lange; R H Williams; L D Hillis
Journal:  Am J Med       Date:  1989-06       Impact factor: 4.965

Review 7.  Hypothesis: Uric acid, nephron number, and the pathogenesis of essential hypertension.

Authors:  Daniel I Feig; Takahiko Nakagawa; S Ananth Karumanchi; William J Oliver; Duk-Hee Kang; Jennifer Finch; Richard J Johnson
Journal:  Kidney Int       Date:  2004-07       Impact factor: 10.612

Review 8.  Could uric acid have a role in acute renal failure?

Authors:  A Ahsan Ejaz; Wei Mu; Duk-Hee Kang; Carlos Roncal; Yuri Y Sautin; George Henderson; Isabelle Tabah-Fisch; Birgit Keller; Thomas M Beaver; Takahiko Nakagawa; Richard J Johnson
Journal:  Clin J Am Soc Nephrol       Date:  2006-12-06       Impact factor: 8.237

9.  Efficacy of allopurinol pretreatment for prevention of contrast-induced nephropathy: a randomized controlled trial.

Authors:  T Erol; A Tekin; M T Katırcıbaşı; N Sezgin; M Bilgi; G Tekin; A Zümrütdal; A T Sezgin; H Müderrisoğlu
Journal:  Int J Cardiol       Date:  2012-05-08       Impact factor: 4.164

10.  Association between serum uric acid and development of type 2 diabetes.

Authors:  Satoru Kodama; Kazumi Saito; Yoko Yachi; Mihoko Asumi; Ayumi Sugawara; Kumiko Totsuka; Aki Saito; Hirohito Sone
Journal:  Diabetes Care       Date:  2009-06-23       Impact factor: 19.112

View more
  15 in total

Review 1.  Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation.

Authors:  Richard J Johnson; George L Bakris; Claudio Borghi; Michel B Chonchol; David Feldman; Miguel A Lanaspa; Tony R Merriman; Orson W Moe; David B Mount; Laura Gabriella Sanchez Lozada; Eli Stahl; Daniel E Weiner; Glenn M Chertow
Journal:  Am J Kidney Dis       Date:  2018-02-27       Impact factor: 8.860

2.  Potential Role of Allopurinol in Preventing Contrast-Induced Nephropathy in Patients Undergoing Percutaneous Coronary Intervention: A Randomized Placebo-Controlled Trial.

Authors:  Zahra Ghelich Khan; Azita Hajhossein Talasaz; Hamidreza Pourhosseini; Kianoush Hosseini; Mohammad Javad Alemzadeh Ansari; Arash Jalali
Journal:  Clin Drug Investig       Date:  2017-09       Impact factor: 2.859

Review 3.  Role of Uric Acid Metabolism-Related Inflammation in the Pathogenesis of Metabolic Syndrome Components Such as Atherosclerosis and Nonalcoholic Steatohepatitis.

Authors:  Akifumi Kushiyama; Yusuke Nakatsu; Yasuka Matsunaga; Takeshi Yamamotoya; Keiichi Mori; Koji Ueda; Yuki Inoue; Hideyuki Sakoda; Midori Fujishiro; Hiraku Ono; Tomoichiro Asano
Journal:  Mediators Inflamm       Date:  2016-12-14       Impact factor: 4.711

Review 4.  Are There Modifiable Risk Factors to Improve AKI?

Authors:  Sasa Nie; Li Tang; Weiguang Zhang; Zhe Feng; Xiangmei Chen
Journal:  Biomed Res Int       Date:  2017-07-04       Impact factor: 3.411

Review 5.  Serum uric acid and acute kidney injury: A mini review.

Authors:  Kai Hahn; Mehmet Kanbay; Miguel A Lanaspa; Richard J Johnson; A Ahsan Ejaz
Journal:  J Adv Res       Date:  2016-09-24       Impact factor: 10.479

6.  N-acetyl cysteine versus allopurinol in the prevention of contrast nephropathy in patients with chronic kidney disease: A randomized controlled trial.

Authors:  R Sadineni; K R Karthik; G Swarnalatha; U Das; G Taduri
Journal:  Indian J Nephrol       Date:  2017 Mar-Apr

7.  Protective role of fructokinase blockade in the pathogenesis of acute kidney injury in mice.

Authors:  Ana Andres-Hernando; Nanxing Li; Christina Cicerchi; Shinichiro Inaba; Wei Chen; Carlos Roncal-Jimenez; Myphuong T Le; Michael F Wempe; Tamara Milagres; Takuji Ishimoto; Mehdi Fini; Takahiko Nakagawa; Richard J Johnson; Miguel A Lanaspa
Journal:  Nat Commun       Date:  2017-02-13       Impact factor: 14.919

Review 8.  Hyperuricemia in Kidney Disease: A Major Risk Factor for Cardiovascular Events, Vascular Calcification, and Renal Damage.

Authors:  Abutaleb Ahsan Ejaz; Takahiko Nakagawa; Mehmet Kanbay; Masanari Kuwabara; Ada Kumar; Fernando E Garcia Arroyo; Carlos Roncal-Jimenez; Fumihiko Sasai; Duk-Hee Kang; Thomas Jensen; Ana Andres Hernando; Bernardo Rodriguez-Iturbe; Gabriela Garcia; Dean R Tolan; Laura G Sanchez-Lozada; Miguel A Lanaspa; Richard J Johnson
Journal:  Semin Nephrol       Date:  2020-11       Impact factor: 5.299

9.  Effectiveness of N-Acetylcysteine for the Prevention of Contrast-Induced Nephropathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Renfan Xu; Anyu Tao; Yang Bai; Youbin Deng; Guangzhi Chen
Journal:  J Am Heart Assoc       Date:  2016-09-23       Impact factor: 5.501

10.  Allopurinol prophylactic therapy and the prevention of contrast-induced nephropathy in high-risk patients undergoing coronary angiography: A prospective randomized controlled trial.

Authors:  Leili Iranirad; Mohammad Saleh Sadeghi; Ahmadreza Bagheri; Kobra Doostali; Samieh Norouzi; Seyed Fakhreddin Hejazi; Hossein Saghafi; Sakineh Roshani-Mobaraki
Journal:  ARYA Atheroscler       Date:  2017-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.